Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs).

Authors: Eileen M. O'Reilly, Teresa Macarulla, Laetitia Dahan, Ivan Borbath, Philippe Alexandre Cassier, Florent Guelfucci, Armel Ngami, Yago Pico de Coaña, Zev A. Wainberg, Sumeet Vijay Ambarkhane, Jean-Luc Van Laethem

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.723

Source: Full article

---

Abstract

723